Clinical Trial Update: Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children [Phase 3]

View source ↗

Summary

Phase 3 persistence and booster study of GSK134612 meningococcal vaccine in healthy children completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal, Meningococcal Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2019-01-31